XOLAIR is FDA-approved for use in appropriate patients with Allergic Asthma and also appropriate patients with chronic idiopathic urticaria (CIU).
XOLAIR is administered subcutaneously every 2 or 4 weeks for Allergic Asthma and every 4 weeks for CIU. 1 Because the solution is slightly viscous, the injection may take 5 to 10 seconds to administer. XOLAIR injections may be administered in your office or at an appropriate injection facility that administers XOLAIR.
There are 2 options in XOLAIR formulation, Vial or PFS
Administer XOLAIR only in a healthcare setting by healthcare providers prepared to manage anaphylaxis that can be life-threatening. For more information on anaphylaxis, read Boxed Warning.
Be sure to review the full prescribing information, including Medication Guide, before administering XOLAIR to patients. Also, provide and instruct patients to read the XOLAIR Medication Guide before starting treatment and before each subsequent treatment.
Option 1: Use a Prefilled Syringe
- No reconstitution required
Preparation & Administration
Click on this video to see proper instructions on how to prepare and inject XOLAIR prefilled syringe
Click the tabs below, to learn more about preparing and administering the prefilled syringe
Option 2: Reconstitute From a Vial
Supplies Needed to Reconstitute the Vial and Administer XOLAIR
Once the correct dose has been determined and the necessary supplies have been assembled, you are ready to begin.
Click the tabs below, to learn more about how to prepare the XOLAIR vial, reconstitute the dose, and administer the injection.
After reconstitution, the XOLAIR solution is somewhat viscous and will appear clear or slightly opalescent. It is acceptable if there are a few small bubbles or foam around the edge of the vial; there should be no visible gel-like particles in the reconstituted solution. Do not use if foreign particles are present.
Stability After Reconstitution
The solution should be used for subcutaneous administration within 8 hours following reconstitution when refrigerated in the vial at 2°C to 8°C (36°F to 46°F) or within 4 hours of reconstitution when stored at room temperature. Reconstituted XOLAIR vials should be protected from direct sunlight.
XOLAIR is for single use only and contains no preservatives.
Note: Each XOLAIR vial delivers 150 mg of XOLAIR per 1.2 mL upon reconstitution with 1.4 mL of SWFI, USP.
SELECTED IMPORTANT SAFETY INFORMATION
Anaphylaxis presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR. Anaphylaxis has occurred as early as after the first dose of XOLAIR, but also has occurred beyond 1 year after beginning regularly administered treatment. Because of the risk of anaphylaxis, observe patients closely for an appropriate period of time after XOLAIR administration. Health care providers administering XOLAIR should be prepared to manage anaphylaxis that can be life-threatening. Inform patients of the signs and symptoms of anaphylaxis and instruct them to seek immediate medical care should symptoms occur.
Spoilage Replacement Program
If the XOLAIR prescribed for a labeled indication was spoiled and unable to be administered, the product might be eligible for replacement through the Genentech Spoilage Replacement Program.*
*Subject to certain limitations and conditions. The Spoilage Replacement Program covers infused or injected Genentech products.
Contact a Representative
Fill out a contact form to get in touch with a XOLAIR representative to find out more about XOLAIR.